Week 1 · Essay
Coming · Week 1 · Q2 2028
The macro case for Longevity & Bioengineering
Why now — the tailwinds, policy shifts, and capital flows we're reading.
SECTOR · 16
In the pipelineLongevity & Bioengineering
Long, scientific, and capital-intensive — but the most asymmetric upside if the early bets compound.
45-day editorial cycle
Q2 2028
W1
Macro
W2
Unit Econ
W3
Landscape + Interview
W4
White Spaces
W5
Flagship Report
W6
Recap + Panel
The essays.
Five essays · Monday mornings
Week 2 · Essay
Coming · Week 2 · Q2 2028
The unit economics of Longevity & Bioengineering
Margin structure, capex, payback, and the shape of a 10x winner.
Week 3 · Essay
Coming · Week 3 · Q2 2028
Landscape map of Longevity & Bioengineering
Incumbents, challengers, recent funding, M&A, and strategic moves.
Week 4 · Essay
Coming · Week 4 · Q2 2028
Where the next winners will emerge
Unsolved problems, contrarian theses, and what's being mispriced.
Week 6 · Essay
Coming · Week 6 · Q2 2028
Recap & revisions
What we learned over six weeks. What we got wrong. Where we stand.
The big one.
Week 5 · 30 pages · free, no email gate
Coming Week 5 · Q2 2028
The Bottomline Longevity & Bioengineering Report
A 25–40 page PDF — full sector breakdown, Bottomline Scorecard, teardowns, white-space theses.
Reserve a copy →On camera.
Two conversations · 25–45 min each
Week 3 · Operator Interview
Operator interview
A 25-45 minute conversation with a founder or operator inside the sector.
Coming · Week 3 · Q2 2028
Week 6 · Panel Discussion
Panel: Where we might be wrong
A debate-format conversation on the assumptions we're making.
Coming · Week 6 · Q2 2028
Building in Longevity & Bioengineering?
Three lines is enough. Real revenue, real customers, real numbers. Get it in before this cycle wraps — we're paying close attention right now.